Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Frank Bennett

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Antisense & Nucleic Acid Drug Development|August 7, 2002
Efficiency of antisense oligonucleotide drug discoveryC Frank Bennett
Annual Review of Medicine|January 30, 2019
Therapeutic Antisense Oligonucleotides Are Coming of AgeC Frank Bennett
Annual Review of Pharmacology and Toxicology|January 9, 2010
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platformC Frank Bennett, Eric E Swayze
Neuron|June 24, 2023
Antisense drugs for rare and ultra-rare genetic neurological diseasesMadelyn E McCauley, C Frank Bennett
Oncogene|December 10, 2003
Antisense oligonucleotide-based therapeutics for cancerNicholas M Dean, C Frank Bennett
Nucleic Acids Research|December 18, 2004
Sequence-dependent cytotoxicity of second-generation oligonucleotidesDenis Drygin, Stephen Barone, C Frank Bennett
Advances in Experimental Medicine and Biology|September 10, 2014
Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defectsFrank Rigo, Punit P Seth, C Frank Bennett
The Journal of Clinical Investigation|January 29, 2019
Selective tissue targeting of synthetic nucleic acid drugsPunit P Seth, Michael Tanowitz, C Frank Bennett
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1Johanna E Lee, C Frank Bennett, Thomas A Cooper
Annual Review of Pharmacology and Toxicology|October 9, 2020
Antisense Drugs Make Sense for Neurological DiseasesC Frank Bennett, Holly B Kordasiewicz, Don W Cleveland
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Antisense & Nucleic Acid Drug Development|August 7, 2002
Efficiency of antisense oligonucleotide drug discoveryC Frank Bennett
Annual Review of Medicine|January 30, 2019
Therapeutic Antisense Oligonucleotides Are Coming of AgeC Frank Bennett
Annual Review of Pharmacology and Toxicology|January 9, 2010
RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platformC Frank Bennett, Eric E Swayze
Neuron|June 24, 2023
Antisense drugs for rare and ultra-rare genetic neurological diseasesMadelyn E McCauley, C Frank Bennett
Oncogene|December 10, 2003
Antisense oligonucleotide-based therapeutics for cancerNicholas M Dean, C Frank Bennett
Nucleic Acids Research|December 18, 2004
Sequence-dependent cytotoxicity of second-generation oligonucleotidesDenis Drygin, Stephen Barone, C Frank Bennett
Advances in Experimental Medicine and Biology|September 10, 2014
Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defectsFrank Rigo, Punit P Seth, C Frank Bennett
The Journal of Clinical Investigation|January 29, 2019
Selective tissue targeting of synthetic nucleic acid drugsPunit P Seth, Michael Tanowitz, C Frank Bennett
Proceedings of the National Academy of Sciences of the United States of America|February 29, 2012
RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1Johanna E Lee, C Frank Bennett, Thomas A Cooper
Annual Review of Pharmacology and Toxicology|October 9, 2020
Antisense Drugs Make Sense for Neurological DiseasesC Frank Bennett, Holly B Kordasiewicz, Don W Cleveland
Pageof 17